中国生物制药(01177.HK) 公布，旗下“洛索洛芬钠凝胶贴膏”已获得中国国家药品监督管理局的上市批准，用于消炎及镇痛包括骨关节炎、肌肉痛、外伤所致的肿胀疼痛。
据介绍，洛索洛芬钠是一种苯丙酸类非甾体消炎药，通过抑制环氧化酶、阻断前列腺素合成，进而起到抗炎、解热、镇痛的作用。与其他非甾体抗炎药相比，洛索洛芬钠为前体药物，安全耐受性较好。(js/k)
(港股报价延迟最少十五分钟。沽空资料截至 2025-02-06 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.